Surfkast, I know that you'd like to change your decision of when to buy, hold or sell from a week or so ago, but my only advice is to set your target further out. What will IOVA be following Q2 results, Q3 results, and into next year when we see the chance of this TIL therapy getting approved for NSCLC. I can also say that I wish I sold everything when we hit $18, and I would then buy it all back today (or would I). I might have walked away instead of looking for ways to build my position.
There's 100's of reasons to sell, but only one reason to buy, and that's the expectation of profit. I expect that Iovance will not only be profitable, but IOVA the stock will see higher highs this year. These are my opinions based on my own due diligence.
You do have a few posters on this board that offer some great insights as to reasons to stay long, but you won't see many of us trying to predict day to day movements (even when we're trying to trade on the short term). We will occasionally share our thoughts about some of our future expectations, but all of your trading and investing decisions have to be your own.
This board is proving to be a great place to share a few ideas, concerns, insights, and supporting evidence for investing in IOVA. Thanks for moderating and keeping an eye on it so that it doesn't turn into just another board filled with valueless posts.
Good luck.
Badgerkid
There's 100's of reasons to sell, but only one reason to buy, and that's the expectation of profit. I expect that Iovance will not only be profitable, but IOVA the stock will see higher highs this year. These are my opinions based on my own due diligence.
You do have a few posters on this board that offer some great insights as to reasons to stay long, but you won't see many of us trying to predict day to day movements (even when we're trying to trade on the short term). We will occasionally share our thoughts about some of our future expectations, but all of your trading and investing decisions have to be your own.
This board is proving to be a great place to share a few ideas, concerns, insights, and supporting evidence for investing in IOVA. Thanks for moderating and keeping an eye on it so that it doesn't turn into just another board filled with valueless posts.
Good luck.
Badgerkid
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/22/2026 09:15:00 PM
- Iovance Biotherapeutics to Present at Upcoming Conference • GlobeNewswire Inc. • 05/21/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:18:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:16:23 PM
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 11:05:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/01/2026 09:00:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:05:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 09:01:20 PM
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
